NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

STEMCELL Technologies Wins Deloitte Best Managed Companies Award - STEMCELL Technologies is proud to announce that the company has been selected as a winner of Canada’s Best Managed Companies program for 2019 - Deloitte.com / STEMCELL.com
STEMCELL Technologies Wins Deloitte Best Managed Companies Award

 

NewswireTODAY - /newswire/ - Vancouver, British Columbia, Canada, 2019/03/08 - STEMCELL Technologies is proud to announce that the company has been selected as a winner of Canada’s Best Managed Companies program for 2019 - Deloitte.com / STEMCELL.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Canada's Best Managed Companies is the country’s leading business awards program, recognizing excellence in the management abilities and practices of Canadian owned and managed companies with revenues over $15 million.

STEMCELL Technologies is Canada’s largest biotechnology company. Privately owned and headquartered in Vancouver, the company develops specialized cell culture media, cell isolation systems, accessory products, and scientific services that are used by life sciences researchers working in the cell therapy, cancer research, and regenerative medicine fields. STEMCELL provides high-quality scientific tools and services to 22 countries directly, and more than 100 countries via distributors.

“I am thrilled that STEMCELL Technologies has been chosen to receive this prestigious award. Our goal at STEMCELL is simply to be Scientists Helping Scientists, supporting cancer researchers and other scientists around the world. That motto is embodied in how the company is managed at every level. We pride ourselves in providing meaningful, well-paid jobs with strong career trajectories for scientists and other professionals. We are also committed to keeping this expertise and intellectual property on Canadian soil, which makes this particular recognition especially meaningful.” stated Dr. Allen Eaves, STEMCELL’s Founder, President, and CEO.

STEMCELL Technologies (stemcell.com) currently employs more than 1200 individuals, approximately 900 of whom are based in Vancouver, Canada. Over two-thirds of all employees hold bachelor level degrees, with more than one-third also holding advanced degrees, such as a PhD, MSc, MBA, Masters in Engineering or law degree. With more than 40 languages spoken across the company and a greater than 50% female workforce at all levels, STEMCELL prides itself on being an equal opportunity employer. Rooted in the belief that learning drives innovation, STEMCELL invests heavily in programming to support employee training, leadership development, communication, and engagement.

Since its inception in 1993, STEMCELL’s annual growth rate has been ~20% per year, with current sales of over $200 million. Focused on long-term growth, STEMCELL reinvests all profits into the company. STEMCELL’s goal is to see global sales of over $1 billion and 5,000 employees by 2029. The company is well positioned to realize this growth, with hundreds of new products in its Research & Development pipeline and a strong patent and intellectual property library.

STEMCELL Technologies would like to formally thank the sponsors of the Canada’s Best Managed Companies program, including Deloitte Private, CIBC, Canadian Business, Smith School of Business, and TMX, as well as the independent review committee. We are honoured to receive this recognition, and we are excited and motivated to continue to support Canadian innovation and global scientific discovery.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


STEMCELL Technologies Wins Deloitte Best Managed Companies Award

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Deloitte Best Managed | STEMCELL Technologies Inc
Contact: Andrew Booth - STEMCELL.com 
604-877-0713 public.relations[.]stemcell.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory Diseases
OPDIVO® Intravenous Infusion Approved in South Korea for the Treatment of Resectable Non-Small Cell Lung Cancer
Ipsen Completes Acquisition of Memo Therapeutics AG, Adding First-in-class Asset to Ipsen’s Rare Disease Pipeline
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study
Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)